Anti-p200 pemphigoid
British Journal of Dermatology · 06.01.2026 · 194 (1) · 10-17
DOI: 10.1093/bjd/ljaf324 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Dermatology, online erschienen am 25.08.2025. Verfasst von Michael Kasperkiewicz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Autoantibodies, Laminin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Anti-p200 pemphigoid is an autoimmune bullous disorder, first described in 1996. Clinically, it presents with tense blisters, erosions, crusts and erythematous macules/plaques, in addition to mucosal involvement in about 40% of cases, resembling bullous pemphigoid or the inflammatory variant of epidermolysis bullosa acquisita. As in other pemphigoid diseases, autoreactive IgG and/or C3 bind along the cutaneous basement membrane zone. Serum autoantibodies recognize a 200 kDa protein of the dermoepidermal junction that label the dermal side of human salt-split skin by indirect immunofluorescence microscopy. Subsequently, laminin γ1 has been described as a target antigen of anti-p200 pemphigoid. Laminin β4 has also recently been identified as a target antigen. A standardized, highly specific and sensitive detection system for serum anti-laminin β4 IgG is now widely available. This allows for the diagnosis of anti-p200 pemphigoid outside of specialized centres. Current in vitro and ex vivo data point to laminin β4 as the pathophysiologically relevant autoantigen, while in vivo data to clarify the functional relevance of anti-laminin β4 IgG are still lacking. Here, we summarize the current knowledge about the epidemiology, clinical presentation, diagnosis, target antigens, pathophysiology and treatment of this pemphigoid disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
- University Clinic of Dermatology and Allergy, University of Oldenburg, Oldenburg, Germany.
- Department of Dermatology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
ORCID-Profile: Enno Schmidt
Zitieren
APA
Kasperkiewicz, M., Pigors, M., Holtsche, M. M., Goletz, S., & Schmidt, E. (2026). Anti-p200 pemphigoid. British Journal of Dermatology, 194(1), 10-17. https://doi.org/10.1093/bjd/ljaf324
Vancouver
Kasperkiewicz M, Pigors M, Holtsche MM, Goletz S, Schmidt E. Anti-p200 pemphigoid. British Journal of Dermatology. 2026;194(1):10-17. doi:10.1093/bjd/ljaf324
BibTeX
@article{Kasperkiewicz2026,
author = {Kasperkiewicz, Michael and Pigors, Manuela and Holtsche, Maike M and Goletz, Stephanie and Schmidt, Enno},
title = {Anti-p200 pemphigoid},
journal = {British Journal of Dermatology},
year = {2026},
volume = {194},
number = {1},
pages = {10--17},
doi = {10.1093/bjd/ljaf324}
}
EUVIMED